Welcome to our dedicated page for Innate Pharma S.A. ADS news (Ticker: IPHA), a resource for investors and traders seeking the latest updates and insights on Innate Pharma S.A. ADS stock.
Innate Pharma S.A. (Symbol: IPHA) is a clinical-stage biotechnology company at the forefront of cancer treatment innovation. Specializing in immuno-oncology, Innate Pharma develops first-in-class therapeutic antibodies designed to harness the innate immune system. This pioneering approach helps the body's natural defenses recognize and combat cancer cells more effectively.
The company's diverse pipeline includes four clinical-stage antibodies along with several preclinical candidates. Key products under development include lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401, and IPH6501. These therapies aim to address a wide range of cancer types, particularly those with high unmet medical needs.
Innate Pharma has made significant strides in the discovery and development of checkpoint inhibitors, leveraging its deep understanding of natural killer cell biology. This expertise has led to strategic partnerships with renowned biopharmaceutical companies such as AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S, and Sanofi.
The company’s revenue streams primarily come from research collaborations, licensing agreements, and milestone payments from its pharmaceutical partners. Innate Pharma's proprietary platform, ANKET (Antibody-based NK cell Engager Therapeutics), forms the backbone of its innovative therapeutic strategies.
With a commitment to advancing cancer treatment, Innate Pharma continues to make significant progress in clinical trials and research, aiming to bring transformative therapies to patients worldwide.
Innate Pharma announced that its anti-CD39 monoclonal antibody, IPH5201, will advance to a Phase 2 clinical trial in lung cancer. The company will receive a
Innate Pharma (Euronext: IPH; Nasdaq: IPHA) has announced the results of its Annual General Meeting (AGM) held on May 20, 2022, in Marseille, France. A quorum of 40.88% was reached with 134 votes cast from a total of 32,598,725 shares. Notably, Dr. Sally Bennett has been appointed to the Supervisory Board and will also serve on the Audit Committee. She brings over 20 years of experience in finance and life sciences. Additionally, Mr. Patrick Langlois has resigned from the Board after 12 years of service.
Innate Pharma SA (Euronext: IPH; Nasdaq: IPHA), a clinical-stage biotech company focused on oncology, announced participation in key investor conferences. The H.C. Wainwright Annual Global Life Sciences Conference will take place from May 23-25, 2022, followed by Citi’s European Healthcare Conference on June 16, 2022. Innate Pharma aims to enhance cancer treatment through innovative antibodies targeting the immune system, supported by collaborations with major biopharmaceutical companies. The company is headquartered in Marseille, France, with a US office in Rockville, MD.
Innate Pharma (IPHA) announced significant progress in its clinical pipeline, highlighted by the first patient dosed in AstraZeneca's Phase 3 clinical trial, PACIFIC-9, triggering a $50 million milestone payment. This will enhance the company's cash position to €131.7 million as of March 31, 2022. Revenue for Q1 2022 was €2.6 million, down from €4.5 million year-over-year, primarily from collaboration agreements. The company is optimistic about future clinical milestones and updates on its diverse pipeline of immuno-oncology treatments.
On May 1, 2022, Innate Pharma reported its outstanding shares and voting rights per French market regulations. The company has a total of 79,753,657 ordinary shares and 6,514 Preferred Shares 2016, along with 7,581 Preferred Shares 2017. The total theoretical voting rights amount to 80,511,497, while the exercisable voting rights stand at 80,492,922. These figures ensure transparency in shareholding and align with AMF regulations. Innate Pharma is focused on oncology, leveraging its expertise in therapeutic antibodies.
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) has filed a prospectus supplement with the SEC for an At-The-Market (ATM) program to offer and sell up to $75 million in American Depositary Shares (ADS). The proceeds will support R&D and general corporate purposes. The company plans to issue up to 23,673,831 ADSs, potentially diluting shareholder value by approximately 26%. Qualified institutional buyers and accredited investors will be eligible for purchase. The program's effectiveness depends on market conditions and may be updated quarterly on the company’s website.
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) will host a conference call on May 10, 2022, at 2 p.m. CEST to discuss its business progress in Q1 2022. The call will feature key executives, including CEO Mondher Mahjoubi and CFO Frédéric Lombard. Participants can join via webcast or telephone. Innate Pharma is dedicated to oncology innovations through therapeutic antibodies, aiming to enhance treatment outcomes for cancer patients. They have significant collaborations with top biotech firms, strengthening their pipeline against high unmet medical needs.
Innate Pharma announced the first patient dosing in the Phase 3 PACIFIC-9 trial for patients with unresectable Stage III non-small cell lung cancer (NSCLC). This trial evaluates the efficacy of durvalumab in combination with monalizumab or oleclumab. The initiation of the trial triggers a $50 million milestone payment from AstraZeneca to Innate, strengthening its cash position. The PACIFIC-9 study aims to assess whether these combinations improve treatment outcomes following standard platinum-based concurrent chemoradiation therapy.
Innate Pharma (Euronext Paris: IPH; Nasdaq: IPHA) will host its Annual General Meeting (AGM) on May 20, 2022, at 10:30 a.m. CEST in Marseille, France. The AGM will be broadcasted live, and only registered shareholders can participate. Shareholders must register their shares at least two business days before the AGM. The Notice of Meeting published on April 8, 2022, includes the agenda and proposed resolutions. Documentation for the AGM is available on the Company’s website.
Innate Pharma announced the filing of its 2021 Universal Registration Document with the French market authority AMF and its annual report on Form 20-F with the SEC. Both filings cover the year ending December 31, 2021, and are accessible via the company's and regulatory websites. Innate Pharma focuses on developing therapeutic antibodies for cancer treatment, supported by partnerships with major biopharmaceutical companies. The company is based in Marseille, France, and trades on Euronext Paris and Nasdaq under the ticker IPHA.
FAQ
What is the current stock price of Innate Pharma S.A. ADS (IPHA)?
What is the market cap of Innate Pharma S.A. ADS (IPHA)?
What does Innate Pharma S.A. specialize in?
What are some of Innate Pharma's key products?
How does Innate Pharma generate revenue?
Who are some of Innate Pharma's notable partners?
What is ANKET?
What is the focus of Innate Pharma’s current projects?
What stage is Innate Pharma in?
What makes Innate Pharma's approach unique?
What is immuno-oncology?
How does Innate Pharma contribute to cancer research?
